Rezultati - Parviz Ghahramani
- Showing 1 - 7 results of 7
-
1
-
2
-
3
-
4
Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule od José Baselga, Xavier Carbonell, Noel-Jaime Castañeda-Soto, Michael Clemens, Michael Green, Vernon Harvey, Serafín Morales, Claire Barton, Parviz Ghahramani
Izdano 2005Artigo -
5
Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer od U. Gatzemeier, G. Groth, Charles Butts, Nico van Zandwijk, Frances A. Shepherd, Andrea Ardizzoni, Claire Barton, Parviz Ghahramani, Vera Hirsh
Izdano 2003Artigo -
6
-
7
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO od Ragy R. Girgis, Mark Slifstein, Deepak Cyril D’Souza, Yih Lee, Antonia Periclou, Parviz Ghahramani, I. Laszlovszky, Suresh Durgam, Nika Adham, Nabeel Nabulsi, Yiyun Huang, Richard E. Carson, Béla Kiss, Margit Kapás, Anissa Abi‐Dargham, Ashok Rakhit
Izdano 2016Artigo
Iskalna orodja:
Sorodne teme
Medicine
Internal medicine
Pharmacokinetics
Pharmacology
Adverse effect
Breast cancer
Cancer
Engineering
Gastroenterology
Law
Oncology
Pathology
Political science
Psychiatry
Trastuzumab
Alternative medicine
Anesthesia
Antifungal
Bioavailability
Biochemical engineering
Bioequivalence
Biology
Biopharmaceutical
Biopharmaceutics Classification System
Biotechnology
Business
Chemistry
Chemotherapy
Cisplatin
Cohort